INTRODUCTION: It is unclear whether quantitating muscle endurance adds nonredundant information useful for the care of patients with muscular disease. METHODS: Records were retrospectively reviewed for all Johns Hopkins Myositis Center patients with a muscle endurance assessment (n = 128, 226 patient-visits). Muscle endurance and strength were quantitated with the Myositis Functional Index-2 (FI2) and manual muscle testing (MMT), respectively. RESULTS: Composite FI2 muscle endurance scores were comparable in inclusion body myositis (n = 58), dermatomyositis (n = 31), and polymyositis (n = 39). Overall, muscle endurance correlated with and evolved similarly to strength, inversely to serum creatine kinase. However, in patients with normal or near-normal strength (mean MMT > 9.75/10), muscle endurance was typically abnormal and highly variable (mean FI2, 5.6/10; interquartile range, 3.3-7.8/10). DISCUSSION: Muscle endurance testing may identify muscle impairment inadequately described by MMT, particularly in patients with high MMT scores. Muscle Nerve 59:70-75, 2019.
INTRODUCTION: It is unclear whether quantitating muscle endurance adds nonredundant information useful for the care of patients with muscular disease. METHODS: Records were retrospectively reviewed for all Johns Hopkins Myositis Centerpatients with a muscle endurance assessment (n = 128, 226 patient-visits). Muscle endurance and strength were quantitated with the Myositis Functional Index-2 (FI2) and manual muscle testing (MMT), respectively. RESULTS: Composite FI2 muscle endurance scores were comparable in inclusion body myositis (n = 58), dermatomyositis (n = 31), and polymyositis (n = 39). Overall, muscle endurance correlated with and evolved similarly to strength, inversely to serum creatine kinase. However, in patients with normal or near-normal strength (mean MMT > 9.75/10), muscle endurance was typically abnormal and highly variable (mean FI2, 5.6/10; interquartile range, 3.3-7.8/10). DISCUSSION: Muscle endurance testing may identify muscle impairment inadequately described by MMT, particularly in patients with high MMT scores. Muscle Nerve 59:70-75, 2019.
Authors: Beatriz Y Hanaoka; Laura C Cleary; Douglas E Long; Archana Srinivas; Kirk A Jenkins; Heather M Bush; Catherine P Starnes; Mathew Rutledge; Jidan Duan; Qian Fan; Natasha Fraser; Leslie J Crofford Journal: Clin Rheumatol Date: 2014-11-12 Impact factor: 2.980
Authors: Helene Alexanderson; Maryam Dastmalchi; Mona Esbjörnsson-Liljedahl; Christina H Opava; Ingrid E Lundberg Journal: Arthritis Rheum Date: 2007-06-15
Authors: Helene Alexanderson; Lisbet Broman; Anna Tollbäck; Annika Josefson; Ingrid E Lundberg; Christina H Stenström Journal: Arthritis Rheum Date: 2006-02-15
Authors: Helene Alexanderson; Malin Regardt; Christina Ottosson; Li Alemo Munters; Maryam Dastmalchi; Lara Dani; Ingrid E Lundberg Journal: J Rheumatol Date: 2018-02-01 Impact factor: 4.666
Authors: Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller Journal: Arthritis Care Res (Hoboken) Date: 2011-11 Impact factor: 4.794
Authors: David R Amici; Iago Pinal-Fernandez; Lisa Christopher-Stine; Andrew L Mammen; Marc L Mendillo Journal: Acta Neuropathol Date: 2021-09-09 Impact factor: 17.088